Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
Arbutus Biopharma (ABUS) Stock Price & Analysis
1,102 Followers
ABUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.85 - $3.22
Previous Close$2.99
Volume733.92K
Average Volume (3M)965.69K
Market Cap
$486.09M
Enterprise Value$341.36M
Total Cash (Recent Filing)$146.91M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)-6.5
Beta1.21
Next Earnings
May 04, 2023EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding157,500,000
10 Day Avg. Volume761,064
30 Day Avg. Volume965,691
Standard Deviation0.29
R-Squared0.17
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.97
Price to Sales (P/S)13.17
Price to Cash Flow (P/CF)7665.10
P/FCF Ratio-23.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.75
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.52
Forecast
1Y Price Target
$6.00Price Target Upside98.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Arbutus Biopharma News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.85 and its highest was $3.22 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Currently, no data Available
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is May 04, 2023 which is in 44 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Mar 02, 2023. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.004.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -$0.14.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 162,570,980 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is PRIMECAP Management Co. It holds Arbutus Biopharma Corporation’s shares valued at 819K.
---
Arbutus Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (98.68% Upside)
$6.00 (98.68% Upside)
Hedge Fund Trend
Decreased
By 71.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.30%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
-4.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
Nkarta
―
Scholar Rock Holding
―
Lexicon Pharmaceuticals
―
Poseida Therapeutics
―
C4 Therapeutics
―
---